Ibogaine for Anxiety & General Wellness

The live analytics dashboard below presents aggregated outcome trajectories from MindScape Retreat's 75-patient Anxiety and General Wellness cohort, spanning four clinically distinct sub-populations: generalized anxiety disorder (GAD, n=30), comorbid anxiety-depression (n=25), SSRI discontinuation syndrome (n=12), and general wellness optimization (n=8). This multi-population design reflects ibogaine's transdiagnostic mechanism. the same neurobiological actions that recalibrate the amygdala and quiet default mode network hyperactivity in GAD also drive symptom resolution in comorbid presentations and serotonergic renormalization in SSRI discontinuation syndrome. Three validated instruments serve as the primary measurement framework: the GAD-7 for anxiety severity, the PHQ-9 for depressive comorbidity, and the WEMWBS (Warwick-Edinburgh Mental Wellbeing Scale) for positive psychological functioning.

The inclusion of the WEMWBS alongside symptom-reduction instruments is clinically significant. Most psychiatric outcome research focuses exclusively on the reduction of pathological symptoms, measuring the absence of suffering rather than the presence of wellbeing. The WEMWBS, validated across large population samples and increasingly adopted in psychedelic medicine research, captures positive psychological dimensions including optimism, meaningful engagement, close relationships, and emotional flexibility that the GAD-7 and PHQ-9 are not designed to detect. The dashboard tracks improvement across all three instruments to provide a complete picture of clinical change.

The trajectories above demonstrate a consistency of response across all four sub-populations that supports a unified neurobiological explanation for ibogaine's anxiolytic effects. Anxiety reduction as measured by the GAD-7 follows a rapid-onset pattern, with the steepest decline occurring within the first 72 hours post-treatment. a timeline consistent with ibogaine's documented 5-HT2A serotonergic agonism and sigma-1 receptor activity, both of which modulate amygdala reactivity and threat-processing thresholds on a pharmacological timescale. This rapidity of onset distinguishes ibogaine from SSRIs, which require weeks to produce measurable GAD-7 changes through slower synaptic remodeling pathways.

The WEMWBS trajectory is particularly instructive because it moves in the positive direction, higher scores represent better outcomes, and its improvement parallels the GAD-7 reduction rather than lagging behind it. This simultaneity suggests that ibogaine is not merely relieving pathological symptoms through suppression, but generating genuine positive neurobiological change through BDNF and GDNF upregulation, neuroplasticity enhancement, and the expanded emotional range that follows default mode network quieting. The convergence of symptom reduction on the GAD-7 and wellbeing gain on the WEMWBS within the same treatment window is not typical of pharmacological or psychotherapeutic interventions studied in anxiety disorder research.

The chart below presents baseline and post-treatment scores on the GAD-7 and PHQ-9. the two primary symptom-reduction instruments in this study. The GAD-7 (Generalized Anxiety Disorder 7-item scale) is a widely validated, 7-item self-report instrument scored from 0 to 21, with clinical thresholds at 5 (mild anxiety), 10 (moderate anxiety), and 15 (severe anxiety). It serves both as a diagnostic screening tool and as a continuous outcome measure sensitive to treatment-related change. The PHQ-9 (Patient Health Questionnaire-9) assesses depressive severity across nine DSM-5 criteria, scored from 0 to 27, with thresholds at 5 (mild), 10 (moderate), 15 (moderately severe), and 20 (severe depression). In this cohort, the PHQ-9 captures depressive comorbidity in the 25-patient comorbid sub-population and monitors for any depression emergence in the GAD-primary and wellness groups.

The cohort baseline GAD-7 of 16 situates the average patient in the moderate-to-severe anxiety range, consistent with a population whose symptoms have been insufficiently controlled by prior SSRI, benzodiazepine, or psychotherapy interventions. The PHQ-9 baseline of 14, straddling the moderate-to-moderately-severe threshold, reflects the clinical reality that anxiety and depression in this population are rarely isolated. they co-emerge from shared neurobiological substrates that ibogaine's multi-receptor mechanism addresses simultaneously.

The symptom-reduction picture captured by the GAD-7 and PHQ-9 above is necessary but not sufficient to characterize the clinical change reported by patients in this cohort. A significant portion of what patients describe, and what motivates them to seek treatment in the first place, is the erosion of positive psychological function: the loss of ease, spontaneity, social engagement, and a felt sense of safety in the world. The following chart measures these dimensions directly through the WEMWBS, sleep quality, and the Wellbeing VAS, instruments designed to detect the presence of psychological health rather than merely the absence of diagnosed symptoms. Because the WEMWBS and Wellbeing VAS are positive-direction scales where higher scores indicate better outcomes, they move in the opposite direction to the GAD-7 and PHQ-9 on the charts, and this distinction is important when interpreting the data.

The convergence of anxiety reduction on the GAD-7, depression improvement on the PHQ-9, and wellbeing enhancement on the WEMWBS across a single treatment window provides the empirical foundation for the transdiagnostic mechanism hypothesis: ibogaine does not simply suppress anxiety through one pathway while leaving other dimensions of psychological function unchanged. Instead, it produces a multi-axis neurobiological reorientation, serotonergic rebalancing, amygdala recalibration, default mode network quieting, and BDNF-mediated neuroplasticity. that simultaneously addresses the neurological substrates of anxiety, depression, and impaired wellbeing. This convergence is particularly evident in the comorbid anxiety-depression sub-population, where PHQ-9 and GAD-7 reductions of comparable magnitude from a single session challenge the conventional pharmacological model of treating anxiety and depression as sequentially addressable conditions requiring separate or additive interventions.

The Wellbeing VAS improvement from 25 to 72 on a 0 to 100 scale. the largest absolute gain of any single measure in this study, reflects ibogaine's documented capacity to generate states of psychological openness, gratitude, and relational connection during the treatment experience that consolidate into durable wellbeing improvements through the post-treatment neuroplasticity window. The methodology underlying these findings is presented in the study design section below.